7–11.3) was found [39–40]. Early recognition of acute HCV infection is important as treatment with PEG-IFN and ribavirin (RBV) is more successful in acute when compared with chronic HCV infection. The factors associated with HCV transmission

in MSM would seem to be modifiable and potentially amenable to behaviour change interventions and education. To date there have been no RCTs or intervention studies to reduce transmission of HCV in MSM and this should be an area of research. There is also a need to target interventions to prevent HCV reinfection in MSM in particular when access to the new direct acting antivirals (DAAs) will possibly make treatment more effective and more tolerable. There is evidence of delayed anti-HCV seroconversion in HIV-infected individuals. In one study median time from detection Androgen Receptor Antagonist of HCV RNA to anti-HCV detection was 91 days (range 0–1206 days) with 10% failing to seroconvert after 9 months. A low ALT and low nadir CD4 cell count

were associated with a delayed/null anti-HCV response [41]. If individuals are found to be HCV antibody positive, viral load and genotyping measurement should this website be performed. In keeping with racial differences in the anti-HCV responses to PEG-IFN and RBV, single nucleotide polymorphisms (SNPs) in the vicinity of the IL28B locus on chromosome 19 have been found to be associated with the antiviral response [42–43] and spontaneous clearance of HCV in monoinfected populations [44–45]. The C allele at rs12979860 [46] was associated with a favourable response in patients with chronic genotype 1 HCV/HIV infection but less so in those with genotype 2/3 infection or acute HCV [47]. Although the exact mechanism by which this facilitates response

to exogenous IFN-alpha is yet to be elucidated, there appears to be a favourable influence on early viral kinetics [48]. Whilst the CC genotype is associated with a favourable response to PEG-IFN and ribavirin Selleck Decitabine in patients with genotypes 1 and 4 HCV/HIV infection, other factors including HCV viral load and hepatic fibrosis stage also make significant contributions to SVR [48] and the probability of response to PEG-IFN and RBV may be predicted by using algorithms such as the Prometheus Index [49]. With the advent of DAAs and less reliance on augmentation of the innate immune response by interferon, the influence of IL28B SNPs on treatment response and choice and length of therapy will wane [50]. Screening for HDV and HEV are discussed in Sections 7 and 9. We recommend staging of liver disease should be performed in those with chronic HCV/HIV and HBV/HIV infections (1B). We suggest in patients with chronic hepatitis/HIV infection a non-invasive test as the staging investigation of choice (2B).